Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis

Delotte, J.; Desantis, M.; Frigenza, M.; Quaranta, D.; Bongain, A.; Benchimol, Daniel; Bereder, Jean Marc

doi:10.1016/j.ejogrb.2013.10.026

Cited by 25 publications

(20 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If urine output decreased, further hydration and furosemide were given. The medical oncologist chose the HIPEC regimen, which included mitomycin, oxaliplatin, cisplatin, paclitaxel, and doxorubicin according to the type of cancer [6,[18][19][20][21].…”

Section: Crs/hipec Technique and Treatment Planmentioning

confidence: 99%

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia

Wang

Chen

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

Section: Crs/hipec Technique and Treatment Planmentioning

confidence: 99%

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia

Wang

Chen

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…A MEDLINE search retrieved only three articles: one concerned a wound recurrence of endometrial cancer, and two consisted of a small series of patients with PC. All patients were treated with complete CRS plus HIPEC [27][28][29]. The most recent series [27] involved 13 patients, of whom seven were alive after a follow-up ranging from 1.56 to 124.83 months: three had recurrence and four did not.…”

Section: Peritoneal Carcinomatosis From Endometrial Cancermentioning

confidence: 99%

“…All patients were treated with complete CRS plus HIPEC [27][28][29]. The most recent series [27] involved 13 patients, of whom seven were alive after a follow-up ranging from 1.56 to 124.83 months: three had recurrence and four did not. The other published series was a small group of five patients, two of whom survived without recurrence after 2 and 3 years, and two of whom were living with recurrence after 1 and 3 years [28].…”

Section: Peritoneal Carcinomatosis From Endometrial Cancermentioning

confidence: 99%

Pathology of Peritoneal Surface Malignancies

Ciardi

Giorgio²

2015

Treatment of Peritoneal Surface Malignancies

View full text Add to dashboard Cite

“…The IP route might also allow for a reduction in the toxicity noted with the IV TAP regimen. Since IP based regimens in endometrial cancer had not been well-studied the present phase I study with IP-based TAP was conducted [18]. …”

Section: Introductionmentioning

confidence: 99%

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study

McMeekin

Sill

Walker

et al. 2015

Gynecologic Oncology

View full text Add to dashboard Cite

Objective To determine the maximum tolerated dose (MTD) of a modified paclitaxel/doxorubicin/cisplatin (TAP) regimen which incorporated intraperitoneal (IP) paclitaxel or IP paclitaxel/cisplatin in advanced endometrial cancer. Methods Patients (pts) with FIGO (1998) Stage IIIA/IIIC with positive cytologic washings/ascites, adnexa, or serosa or Stage IV (intraperitoneal disease spread), histologically confirmed endometrial cancer were eligible. The study was designed as a phase I, 3+3 dose escalation study evaluating 5 dose levels (DL). All pts received cycle 1–2 with IV TAP, and cycles 3–6 with IV/IP therapy, on a 21 day schedule. Adverse events were evaluated on cycles 3–4 for dose limiting toxicity (DLT) and dose escalation decisions. Results Twenty-one pts were enrolled, of which 17 were evaluable for DLT. Most pts had Stage IV disease (76%) and serous/clear cell histology (59%). The MTD was determined to be DL3 (cycles 3–6 including paclitaxel 90 mg/m2 IP, doxorubicin 45 mg/m2 IV , cisplatin 50 mg/m2). Three DLT events occurred and were related to grade 3–4 metabolic toxicities. There was one grade 2 sensory neuropathy event and myelosupression was tolerable without the use of G-CSF. 88% of evaluable pts completed 6 cycles of therapy. With a median follow-up of 22 mo, 46% of patients remain progression-free at 2-yr. Conclusion We described an IV/IP based modification of a standard TAP regimen in endometrial cancer. Based on the high rate of completing 6 cycles of therapy, low rates of neuropathy, and promising PFS, further study of IP therapy in endometrial cancer is warranted.

show abstract

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis

Cited by 25 publications

References 14 publications

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia

Pathology of Peritoneal Surface Malignancies

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study

Contact Info

Product

Resources

About